A Small Dose of Ritonavir Corrects Efavirenz and Saquinavir Interaction

The Body Covers: The 8th European Conference on Clinical Aspects and Treatment of HIV-Infection

Coverage provided by Brian A. Boyle, M.D., J.D.

October 28, 2001

Minor Interaction Between Efavirenz and Saquinavir When Combined with Small Doses of Ritonavir in a QD Regimen (Late Breaker Poster 9)
Authored by M. Kurowski, T. Sternfeld, A. Sawyer, et al.

Saquinavir (SQV) levels can be significantly reduced when prescribed with efavirenz (EFV). In a previous pharmacokinetic (PK) study of the saquinavir and efavirenz interaction, it was found that efavirenz reduced the area under the curve (AUC) of saquinavir by 62%, while the AUC of efavirenz remained almost unchanged. However, the addition of ritonavir (RTV) appears to minimize the effect of efavirenz on saquinavir levels. In a trial by Kurowski and colleagues, which was presented as a late breaker poster at the 8th ECCATHI, the PK interaction between efavirenz and saquinavir given with "boosting" doses of ritonavir (all dosed once daily) were evaluated.

Twenty-four healthy volunteers were divided into two treatment arms. Group A received efavirenz 600mg daily for 14 days and on the 15th day added saquinavir 1,600mg and ritonavir 200mg to the daily regimen. Group B received the saquinavir/ritonavir therapy alone for 14 days and on day 15 efavirenz was added for 2 weeks. A pharmacokinetic (PK) profile was performed for each group on days 14 and 28. The PK profile of saquinavir/ritonavir alone was compared to the efavirenz/saquinavir/ritonavir PK profile.

With the addition of efavirenz, the AUC of saquinavir was reduced by 18.9% as compared with saquinavir/ritonavir alone, and the saquinavir Cmax was reduced from 2,340 ng/ml to 2,130 ng/ml, but the trough levels of saquinavir remained unchanged. None of these results were statistically or clinically significant. No raw data on the effects of efavirenz levels were reported although the authors state the "efavirenz concentrations were not significantly influenced by saquinavir."

The authors concluded, "the saquinavir trough levels remained unaffected in this trial when combined with efavirenz. The observed small differences of the AUC and the Cmax for saquinavir are not expected to limit the clinical use of this triple combination."

As we move toward once-daily therapy, pharmacokinetic studies such as this gain increasing importance. Knowing the exact interaction between medications, before we combine them in antiretroviral regimens, is crucial. The proof still lies, however, in showing that a regimen is successful in the treatment of patients and there was no data of that nature presented in this purely PK study.

Previous | Next

More on HIV Medications

Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.

The Body is a service of Body Health Resources Corporation, 250 West 57th Street, New York, NY 10107. The Body and its logos are trademarks of Body Health Resources Corporation, which owns the copyright of The Body's homepage, topic pages, page designs and HTML code. General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.